By John Gapper
Financial Times, January 5 '06
(excerpt)

Pretty soon, the company stops being research-driven and starts to be marketing-driven.... These are enterprises that should be researching and developing innovative treatments that will eventually face competition from generics. A surfeit of reps diverts them from their purpose. "The industry has layered sales forces on top of forces until it has become overwhelming," says Ken Worzel, managing partner of the consultancy Marakon Associates.